The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth
Open accessAbstract
Although the renin angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor-deficient (AT1a-/-) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a-/- mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the beta-galactosidase gene was inserted into the AT1a gene locus in AT1a-/- mice, the site of beta-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a-/- mice, the major site of the beta-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a-/- mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., & Nuseir, N. (1987) · Nature · doi:10.1038/329630a0 · Cited by 1,210
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J. F., Fishman, M. C., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1560 · Cited by 1,200
Self-citationAngiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Sunderkötter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., & Sorg, C. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.3.410 · Cited by 1,120
Essential Hypertension: Renin and Aldosterone, Heart Attack and Stroke
Brunner, H. R., Laragh, J. H., Baer, L., Newton, M. A., Goodwin, F. T., Krakoff, L. R., Bard, R. H., & Bühler, F. R. (1972) · New England Journal of Medicine · doi:10.1056/nejm197203022860901 · Cited by 1,093
Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb.
Arras, M., Ito, W. D., Scholz, D., Winkler, B., Schaper, J., & Schaper, W. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119877 · Cited by 739
Host cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Reid, J. L., & Robertson, J. W. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03228-0 · Cited by 545
Angiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Angiotensin II Type 1a Receptor-deficient Mice with Hypotension and Hyperreninemia
Sugaya, T., Nishimatsu, S.-I., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18719 · Cited by 366
Self-citationTorisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., NAKAYAMA, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · PubMed · Cited by 363
Wang, J., Sun, L., Myeroff, L., Wang, X., Gentry, L. E., Yang, J., Liang, J., Zborowska, E., Markowitz, S., Willson, J. K. V., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.22044 · Cited by 337
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
Volpert, O. V., Ward, W. F., Lingen, M. W., Chesler, L., Solt, D. B., Johnson, M. D., Molteni, A., Polverini, P. J., & Bouck, N. P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118838 · Cited by 323
Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway
Nataraj, C., Oliverio, M. I., Mannon, R. B., Mannon, P. J., Audoly, L. P., Amuchastegui, C. S., Ruiz, P., Smithies, O., & Coffman, T. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7451 · Cited by 308
Williams, B., Baker, A. Q., Gallacher, B., & Lodwick, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.5.913 · Cited by 301
Otani, A., Takagi, H., Suzuma, K., & Honda, Y. (1998) · Circulation Research · doi:10.1161/01.res.82.5.619 · Cited by 266
Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2%3c182::aid-ijc6%3e3.0.co;2-m · Cited by 254
Kojima, M., Shiojima, I., Yamazaki, T., Komuro, I., Zou, Z., Wang, Y., Mizuno, T., Ueki, K., Tobe, K., & Kadowaki, T. (1994) · Circulation · doi:10.1161/01.cir.89.5.2204 · Cited by 250
Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis
Fujita, M., Hayashi, I., Yamashina, S., Itoman, M., & Majima, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00496-5 · Cited by 233
Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages
Okamura, A., Rakugi, H., Ohishi, M., Yanagitani, Y., Takiuchi, S., Moriguchi, K., Fennessy, P. A., Higaki, J., & Ogihara, T. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917040-00012 · Cited by 221
ZIADA, A. M. A. R., HUDLICKA, O., TYLER, K. R., & WRIGHT, A. J. A. (1984) · Cardiovascular Research · doi:10.1093/cvr/18.12.724 · Cited by 205
Tissue Inhibition of Angiotensin-Converting Enzyme Activity Stimulates Angiogenesis In Vivo
Fabre, J.-E., Rivard, A., Magner, M., Silver, M., & Isner, J. M. (1999) · Circulation · doi:10.1161/01.cir.99.23.3043 · Cited by 178
Usui, M., Egashira, K., Tomita, H., Koyanagi, M., Katoh, M., Shimokawa, H., Takeya, M., Yoshimura, T., Matsushima, K., & Takeshita, A. (2000) · Circulation · doi:10.1161/01.cir.101.3.305 · Cited by 161
Miyajima, A., Kosaka, T., Asano, T., Asano, T., Seta, K., Kawai, T., & Hayakawa, M. (2002) · PubMed · Cited by 158
Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice
Hisada, Y., Sugaya, T., Yamanouchi, M., Uchida, H., Fujimura, H., Sakurai, H., Fukamizu, A., & Murakami, K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci2454 · Cited by 152
Self-citationViswanathan, M., Strömberg, C., Seltzer, A. M., & Saavedra, J. M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116043 · Cited by 148
Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis
Sasaki, K., Murohara, T., Ikeda, H., Sugaya, T., Shimada, T., Shintani, S., & Imaizumi, T. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13055 · Cited by 144
Self-citationEvidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis
Sasaki, K., Murohara, T., Ikeda, H., Sugaya, T., Shimada, T., Shintani, S., & Imaizumi, T. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213055 · Cited by 110
Self-citationChymase as a Proangiogenic Factor
Muramatsu, M., Katada, J., Hayashi, I., & Majima, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5545 · Cited by 109
Gorrín-Rivas, M. J., Arii, S., Furutani, M., Mizumoto, M., Mori, A., Hanaki, K., Maeda, M., Furuyama, H., Kondo, Y., & Imamura, M. (2000) · PubMed · Cited by 88
Takeshita, S. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00372-8 · Cited by 61
Warren, J. B., & Loi, R. K. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.5.7896012 · Cited by 53
Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype
Br�cker, E.-B., Zwadlo, G., Suter, L., Brüne, M., & Sorg, C. (1987) · Cancer Immunology Immunotherapy · doi:10.1007/bf00199945 · Cited by 51
Cited by
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption
Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., & Verkman, A. S. (2005) · Nature · doi:10.1038/nature03460 · Cited by 728
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Hunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
Metadata
- Authors
- Egami, K., Murohara, T., Shimada, T., Sasaki, K.-I., Shintani, S., Sugaya, T., Ishii, M., Akagi, T., Ikeda, H., Matsuishi, T., & Imaizumi, T.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-07-01
- Volume
- 112
- Issue
- 1
- Pages
- 67-75
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2111180661
- Cited by
- 345
- References
- 40
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.